Advertisement

Topics

Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?

23:16 EDT 18 Oct 2016 | Nature Publishing

Tyrosine kinase inhibitors (TKIs) are the most common agents used for the treatment of patients with chronic myeloid leukaemia (CML). Several agents are available for frontline treatment, or after the development of resistance or intolerance to agents previously used. Herein, the authors evaluate differences between available TKIs, and discuss several end points that can be considered when selecting the first and subsequent lines of treatment of patients with CML.

Original Article: Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?

NEXT ARTICLE

More From BioPortfolio on "Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?"

Quick Search
Advertisement